| Home | E-Submission | Sitemap | Editorial Office |  
top_img
Clinical and Molecular Hepatology Search > Browse Articles > Search



Favorable effect of corticosteroids in treating acute-on-chronic liver failure underlying chronic hepatitis B
Hyeji Kim, Jung Hyun Kwon, Yong Hee Kim, Soon Woo Nam, Jong Yul Lee, Jeong Won Jang
Clin Mol Hepatol.2018;24(4):430-435.   Published online November 27, 2017     
DOI: https://doi.org/10.3350/cmh.2017.0016
                              
Characterization and evaluation of liver fibrosis grade in patients with chronic hepatitis B virus infection and normal transaminases
San Juan López Cristina, Casado Martín Marta, González Sánchez Mercedes, Porcel Martín Almudena, Hernández Martínez Álvaro, Vega Sáenz Jose Luis, Parrón Carreño Tesifón
Clin Mol Hepatol.2018;24(4):384-391.   Published online July 4, 2018     
DOI: https://doi.org/10.3350/cmh.2018.0004
                                 Cited By 1
Management of chronic hepatitis B patients in immunetolerant phase: what latest guidelines recommend
Grace Lai-Hung Wong
Clin Mol Hepatol.2018;24(2):108-113.   Published online January 22, 2018     
DOI: https://doi.org/10.3350/cmh.2017.0068
                                 Cited By 1
Is it possible to predict the development of an entecavir resistance mutation in patients with chronic hepatitis B in clinical practice?
Joon Yeul Nam, Jeong-Hoon Lee
Clin Mol Hepatol.2017;23(4):311-313.   Published online December 4, 2017     
DOI: https://doi.org/10.3350/cmh.2017.0069
                              
Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir
Hee-Jeong Jeon, Seok Won Jung, Neung Hwa Park, Yujin Yang, Jin-Hee Noh, Jae-Sung Ahn, Hyung Rae Kim, Jae Ho Lee, Jung Woo Shin
Clin Mol Hepatol.2017;23(3):230-238.   Published online June 30, 2017     
DOI: https://doi.org/10.3350/cmh.2017.0003
                                 Cited By 4
Is tenofovir monotherapy a sufficient defense line against multi-drug resistant hepatitis B virus?
Yun Bin Lee, Jeong-Hoon Lee
Clin Mol Hepatol.2017;23(3):219-221.   Published online September 19, 2017     
DOI: https://doi.org/10.3350/cmh.2017.0045
                              
Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B
Won Sohn, Ju-Yeon Cho, Ji Hoon Kim, Jung Il Lee, Hyung Joon Kim, Min-Ah Woo, Sin-Ho Jung, Yong-Han Paik
Clin Mol Hepatol.2017;23(2):170-178.   Published online May 16, 2017     
DOI: https://doi.org/10.3350/cmh.2016.0086
                              Supplementary         Cited By 5
Clinical impact of the early alanine amininotransferase flare during tenofovir monotherapy in treatment-naïve patients with chronic hepatitis B
Hee Yeon Seo, Han Ah Lee, Soon Young Ko, Joon Ho Wang, Jeong Han Kim, Won Hyeok Choe, So Young Kwon
Clin Mol Hepatol.2017;23(2):154-159.   Published online May 8, 2017     
DOI: https://doi.org/10.3350/cmh.2016.0067
                                 Cited By 2
Preemptive antiviral therapy with entecavir can reduce acute deterioration of hepatic function following transarterial chemoembolization
Sun Hong Yoo, Jeong Won Jang, Jung Hyun Kwon, Seung Min Jung, Bohyun Jang, Jong Young Choi
Clin Mol Hepatol.2016;22(4):458-465.   Published online December 25, 2016     
DOI: https://doi.org/10.3350/cmh.2016.0054
                                 Cited By 2
Efficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (SATIS study)
Hye Won Lee, Jun Yong Park, Beom Kyung Kim, Moon Young Kim, Jung Il Lee, Young Suk Kim, Ki Tae Yoon, Kwang-Hyub Han, Sang Hoon Ahn
Clin Mol Hepatol.2016;22(4):443-449.   Published online November 25, 2016     
DOI: https://doi.org/10.3350/cmh.2016.0037
                                 Cited By 5
Switch to tenofovir-based therapy or to continue adefovir-based therapy in CHB patients with suboptimal response to adefovir-based combination?
Byung-Cheol Song
Clin Mol Hepatol.2016;22(4):439-442.   Published online December 25, 2016     
DOI: https://doi.org/10.3350/cmh.2016.0108
                              
New perspectives of biomarkers for the management of chronic hepatitis B
Chih-Lin Lin, Jia-Horng Kao
Clin Mol Hepatol.2016;22(4):423-431.   Published online December 25, 2016     
DOI: https://doi.org/10.3350/cmh.2016.0069
                                 Cited By 17
Comparison of the clinical outcomes between antiviral-naïve patients treated with entecavir and lamivudine-resistant patients receiving adefovir add-on lamivudine combination treatment
Hong Joo Kim, Soo Kyung Park, Hyo Joon Yang, Yoon Suk Jung, Jung Ho Park, Dong Il Park, Yong Kyun Cho, Chong Il Sohn, Woo Kyu Jeon, Byung Ik Kim, Kyu Yong Choi
Clin Mol Hepatol.2016;22(3):350-358.   Published online September 25, 2016     
DOI: https://doi.org/10.3350/cmh.2016.0019
                              
Obesity and hepatocellular carcinoma in patients receiving entecavir for chronic hepatitis B
Jaemin Lee, Sun Hong Yoo, Won Sohn, Hyung Woo Kim, Yong Sun Choi, Jung Ho Won, Jin Young Heo, Sang Jong Park, Young Min Park
Clin Mol Hepatol.2016;22(3):339-349.   Published online September 25, 2016     
DOI: https://doi.org/10.3350/cmh.2016.0021
                                 Cited By 3
Does obesity increase the risk of hepatocellular carcinoma in chronic hepatitis B patients?
Byoung Kuk Jang
Clin Mol Hepatol.2016;22(3):336-338.   Published online September 25, 2016     
DOI: https://doi.org/10.3350/cmh.2016.0104
                              
Tenofovir-associated nephrotoxicity in patients with chronic hepatitis B: two cases
Hyeki Cho, Yuri Cho, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Kook-Hwan Oh, Kyoungbun Lee, Syifa Mustika, Jung-Hwan Yoon, Yoon Jun Kim
Clin Mol Hepatol.2016;22(2):286-291.   Published online June 25, 2016     
DOI: https://doi.org/10.3350/cmh.2015.0066
                                 Cited By 3
The efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adefovir combination therapy
Jeong Han Kim, Sung Hyun Ahn, Soon Young Ko, Won Hyeok Choe, Kyun-Hwan Kim, So Young Kwon
Clin Mol Hepatol.2016;22(2):241-249.   Published online June 15, 2016     
DOI: https://doi.org/10.3350/cmh.2015.0053
                                 Cited By 3
Is the tenofovir based therapy almighty for previous treatment failure in chronic hepatitis B?
Hyung Joon Yim
Clin Mol Hepatol.2016;22(2):238-240.   Published online June 25, 2016     
DOI: https://doi.org/10.3350/cmh.2016.0103
                                 Cited By 1
Comparison of tenofovir plus lamivudine versus tenofovir monotherapy in patients with lamivudine-resistant chronic hepatitis B
Chan Ho Park, Seok Won Jung, Jung Woo Shin, Mi Ae Bae, Yoon Im Lee, Yong Tae Park, Hwa Sik Chung, Neung Hwa Park
Clin Mol Hepatol.2016;22(1):152-159.   Published online March 28, 2016     
DOI: https://doi.org/10.3350/cmh.2016.22.1.152
                              
KASL clinical practice guidelines: management of chronic hepatitis B
The Korean Association for the Study of the Liver (KASL)
Clin Mol Hepatol.2016;22(1):18-75.   Published online March 28, 2016     
DOI: https://doi.org/10.3350/cmh.2016.22.1.18
                                 Cited By 68
Erectile dysfunction in patients with liver disease related to chronic hepatitis B
Min Kim, Seul Young Kim, Woo Sun Rou, Se Woong Hwang, Byung Seok Lee
Clin Mol Hepatol.2015;21(4):352-357.   Published online December 24, 2015     
DOI: https://doi.org/10.3350/cmh.2015.21.4.352
                                 Cited By 8
Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy
Jung Gil Park, Soo Young Park
Clin Mol Hepatol.2015;21(3):242-248.   Published online September 30, 2015     
DOI: https://doi.org/10.3350/cmh.2015.21.3.242
                                 Cited By 1
Static and dynamic prognostic factors for hepatitis-B-related acute-on-chronic liver failure
Jung Min Ha, Won Sohn, Ju Yeon Cho, Jeung Hui Pyo, Kyu Choi, Dong Hyun Sinn, Geum-Youn Gwak, Moon Seok Choi, Joon Hyeok Lee, Kwang Chul Koh, Seung Woon Paik, Byung Chul Yoo, Yong-Han Paik
Clin Mol Hepatol.2015;21(3):232-241.   Published online September 30, 2015     
DOI: https://doi.org/10.3350/cmh.2015.21.3.232
                              
Impact of prior lamivudine use on the antiviral efficacy and development of resistance to entecavir in chronic hepatitis B patients
Joo An Hwang, Kee Bum Kim, Min Jae Yang, Sun Gyo Lim, Jae Chul Hwang, Jae Youn Cheong, Sung Won Cho, Soon Sun Kim
Clin Mol Hepatol.2015;21(2):131-140.   Published online June 26, 2015     
DOI: https://doi.org/10.3350/cmh.2015.21.2.131
                                 Cited By 2
Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients
Sang Kyung Jung, Kyung-Ah Kim, So Young Ha, Hyun Kyo Lee, Young Doo Kim, Bu Hyun Lee, Woo Hyun Paik, Jong Wook Kim, Won Ki Bae, Nam-Hoon Kim, June Sung Lee, Yoon Jung Jwa
Clin Mol Hepatol.2015;21(1):41-48.   Published online March 25, 2015     
DOI: https://doi.org/10.3350/cmh.2015.21.1.41
                                 Cited By 8
The factors associated with longitudinal changes in liver stiffness in patients with chronic hepatitis B
In Ku Yo, Oh Sang Kwon, Jin Woong Park, Jong Joon Lee, Jung Hyun Lee, In Sik Won, Sun Young Na, Pil Kyu Jang, Pyung Hwa Park, Duck Joo Choi, Yun Soo Kim, Ju Hyun Kim
Clin Mol Hepatol.2015;21(1):32-40.   Published online March 25, 2015     
DOI: https://doi.org/10.3350/cmh.2015.21.1.32
                                 Cited By 9
Efficacy of prolonged entecavir monotherapy in treatment-naïve chronic hepatitis B patients exhibiting a partial virologic response to entecavir
Han Na Choi, Jeong Eun Song, Hyeon Chul Lee, Hyeong Ho Jo, Chang Hyeong Lee, Byung Seok Kim
Clin Mol Hepatol.2015;21(1):24-31.   Published online March 25, 2015     
DOI: https://doi.org/10.3350/cmh.2015.21.1.24
                                 Cited By 9
Personalized treatment of hepatitis B
Anna S. Lok
Clin Mol Hepatol.2015;21(1):1-6.   Published online March 25, 2015     
DOI: https://doi.org/10.3350/cmh.2015.21.1.1
                                 Cited By 12
Is it necessary to delay antiviral therapy for 3-6 months to anticipate HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B in endemic areas of HBV genotype C? [corrected-article]
Byung-Cheol Song, Yoo-Kyung Cho, Hyeyoung Jwa, Eun Kwang Choi, Heung Up Kim, Hyun Joo Song, Soo-Young Na, Sun-Jin Boo, Seung Uk Jeong
Clin Mol Hepatol.2014;20(4):355-360.   Published online December 24, 2014     
DOI: https://doi.org/10.3350/cmh.2014.20.4.355
                                 Cited By 2
Serum transferrin as a liver fibrosis biomarker in patients with chronic hepatitis B
Hyo Jung Cho, Soon Sun Kim, Seun Joo Ahn, Joo Han Park, Dong Joon Kim, Young Bae Kim, Sung Won Cho, Jae Youn Cheong
Clin Mol Hepatol.2014;20(4):347-354.   Published online December 24, 2014     
DOI: https://doi.org/10.3350/cmh.2014.20.4.347
                                 Cited By 8
1 | 2 | 3 |
E-Submission
Email Alert
Author's Index
EndNote Style file download
The Korean Association for the Study of the Liver
The Liver Week 2019
SCImago Journal & Country Rank
PubMed Central
PubMed
Scopus
KoreaMed
KoMCI
ScienceCentral
DOAJ
GoogleScholar
Similarity Check
Crossref Cited-by Linking
CrossMark
Funder Registry
ORCID
MeSH on Demand
COPE
Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: kasl@kams.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © The Korean Association for the Study of the Liver. All rights reserved.         
COUNTER
TODAY : 506
TOTAL : 114015